Taselisib

Drug Profile

Taselisib

Alternative Names: GDC 0032; RG-7604

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; Netherlands Cancer Institute
  • Class 3-ring heterocyclic compounds; Amides; Antineoplastics; Benzazepines; Oxazepines; Pyrazoles; Small molecules; Triazoles
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II/III Non-small cell lung cancer
  • Phase I/II Gynaecological cancer
  • Phase I Solid tumours

Most Recent Events

  • 09 Jan 2017 Genentech and Vanderbilt-Ingram Cancer Center suspends patient enrolment in a phase Ib/II trial in Breast cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (NCT02457910)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease, Second-line therapy or greater) in Spain (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease, Second-line therapy or greater) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top